Columbia’s Progesterone Faces FDA Skepticism Over Foreign Data At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.